Peri‑operative Management of Direct Oral Anticoagulants (DOACs)
Procedure Bleeding‑Risk Stratification
- Minimal‑risk procedures (e.g., minor dental work, skin biopsy, cataract surgery) can be performed without stopping DOACs or by holding the dose only on the day of the procedure – European Heart Journal recommendation. 1 (moderate evidence)
- Low‑to‑moderate bleeding‑risk procedures (e.g., cholecystectomy, inguinal hernia repair, colonoscopy with biopsy) require interruption of the DOAC for 24 hours (one dose missed) – American College of Chest Physicians guideline. 2 (high‑quality evidence)
- High‑bleeding‑risk procedures (e.g., major cancer surgery, joint replacement, intracranial surgery, neuraxial anesthesia) require interruption for 48 hours (two to four doses missed) – American College of Chest Physicians guideline. 2 (high‑quality evidence)
- Very high‑bleeding‑risk procedures (intracranial neurosurgery, neuraxial anesthesia) merit a 5‑day interruption to ensure negligible residual anticoagulant effect – French Working Group on Peri‑operative Hemostasis. 3, 4 (moderate evidence)
Factor Xa Inhibitor Interruption (Apixaban, Rivaroxaban, Edoxaban)
| Bleeding‑risk level | Recommended interruption | Key dosing notes | Evidence |
|---|---|---|---|
| Low‑to‑moderate | Hold 24 h (skip 1–2 doses) | If once‑daily evening dose → last dose 2 days before; if twice‑daily or once‑daily morning → last dose the morning of the day before procedure | Anaesthesia (2017) & Chest (2022) & European Heart Journal (2018) (moderate) |
| High | Hold 48 h (skip 2–4 doses) | Same dosing‑timing principles as above | Anaesthesia (2017) & Chest (2022) & European Heart Journal (2018) (moderate) |
| Renal impairment (rivaroxaban, CrCl 15‑29 mL/min) | Extend interruption to 3–4 days | – | Blood (2012) (moderate) |
| Very high | Up to 5 days | – | Anaesthesia (2017) & Anaesthesia (2017) (moderate) |
Dabigatran Interruption (Direct Thrombin Inhibitor)
| Renal function (CrCl) | Bleeding‑risk level | Recommended interruption | Evidence |
|---|---|---|---|
| ≥ 80 mL/min (normal) | Low‑to‑moderate | 24 h (skip 2 doses) | Blood (2012) & European Heart Journal (2018) (moderate) |
| 50‑79 mL/min (mild) | Low‑to‑moderate | 36 h (skip 3 doses) | European Heart Journal (2018) (moderate) |
| 30‑50 mL/min (moderate) | Low‑to‑moderate | 48 h (skip 4 doses) | Blood (2012), Anaesthesia (2017), European Heart Journal (2018) (moderate) |
| ≥ 80 mL/min | High | 48 h (skip 4 doses) | Blood (2012), European Heart Journal (2018) (moderate) |
| 50‑79 mL/min | High | 72 h (skip 6 doses) | European Heart Journal (2018) (moderate) |
| 30‑50 mL/min | High | 96 h (4‑5 days, skip 8 doses) | Blood (2012), Anaesthesia (2017), European Heart Journal (2018) (moderate) |
| Any renal function | Very high | Up to 5 days regardless of CrCl | Anaesthesia (2017) & Anaesthesia (2017) (moderate) |
Renal Function Assessment & Drug Interactions
- Calculate creatinine clearance with the Cockcroft‑Gault formula before deciding interruption duration – Anaesthesia (2017) & Anaesthesia (2017). (moderate)
- Patients with severe renal impairment (CrCl < 30 mL/min) may need additional days beyond standard protocols – American College of Chest Physicians guideline. 2 (high‑quality)
- Recent (within 48 h) serum creatinine values are required; outdated labs should not be used – Anaesthesia (2017) & Anaesthesia (2017). (moderate)
- P‑glycoprotein inhibitors (affect all DOACs, especially dabigatran) warrant extended interruption – Anaesthesia (2017) & Chest (2022). (moderate)
- CYP3A4 inhibitors (affect factor Xa inhibitors) also require longer hold times – Anaesthesia (2017). (moderate)
- Patients ≥ 80 years on dabigatran need special caution and may require longer interruption, particularly for neuraxial procedures – Anaesthesia (2017) & Anaesthesia (2017). (moderate)
Bridging, Laboratory Monitoring, and Neuraxial Anesthesia
- Heparin bridging is not recommended for elective DOAC interruption; it raises bleeding risk without lowering thrombotic risk – Anaesthesia (2017), Anaesthesia (2017), Anaesthesia (2017), Chest (2022). (high‑quality)
- Routine measurement of DOAC plasma levels before elective procedures is unnecessary; standard interruption based on half‑life suffices – Anaesthesia (2017), Anaesthesia (2017), Chest (2022). Measurement may be reserved for urgent/emergent or very high‑risk surgeries. (moderate)
- Neuraxial anesthesia should be avoided when residual DOAC concentrations may be present, especially in elderly patients on dabigatran or those with renal impairment – Anaesthesia (2017), Anaesthesia (2017). (moderate)
Resumption of DOAC Therapy After Procedure
- Low‑bleeding‑risk procedures: resume full dose 24 h after completion – American College of Chest Physicians guideline. 2 (high‑quality)
- High‑bleeding‑risk procedures: resume full dose 48‑72 h after surgery once adequate hemostasis is confirmed – Anaesthesia (2017) & Chest (2022). (moderate)
- Minor procedures with secure hemostasis: restart at least 6 h post‑procedure – Anaesthesia (2017) & Anaesthesia (2017). (moderate)
- If ongoing bleeding or surgical contraindication exists, delay resumption and consider pharmacologic or mechanical thromboprophylaxis – Anaesthesia (2017) & Anaesthesia (2017). (moderate)
Evidence Base
- The 2022 American College of Chest Physicians guideline provides high‑quality evidence supporting the standardized interruption and resumption approach. 2
- The French Working Group on Peri‑operative Hemostasis (2017) offers concordant recommendations with additional granularity for specific clinical scenarios. 5, 3, 6, 4, 7 (moderate)
- The PAUSE study and subsequent analyses demonstrate that this pharmacokinetic‑based strategy yields low thromboembolism rates (0.2‑0.4 %) and major bleeding rates (1‑2 %). 2 (high‑quality)
Guidelines for Continuation of Anticoagulants During Routine Dental Procedures
1. Risk Stratification of Dental Procedures
2. Management of Direct Oral Anticoagulants (DOACs)
2.1 Routine (Low‑Risk) Dental Procedures
2.2 When Interruption Is Considered (Higher‑Risk Surgery)
| DOAC | Low‑risk interruption | High‑risk interruption | |
|---|---|---|---|
| Apixaban, Rivaroxaban, Edoxaban | Skip 1 dose (≈24 h) | Skip 2 doses (≈48 h) | [11] |
| Dabigatran – normal renal function (CrCl ≥ 80 mL/min) | Skip 1 dose (≈24 h) | Skip 2 doses (≈48 h) | [11] |
| Dabigatran – moderate renal impairment (CrCl 30‑50 mL/min) | Skip 2 doses (≈48 h) | Skip 3 doses (≈72 h) | [9] |
| Dabigatran – severe renal impairment (CrCl < 30 mL/min) | Add an additional day to the above intervals | Add an additional day to the above intervals | [11] |